Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Centre of Medical Genetics, |
RCV000663461 | SCV002025477 | pathogenic | Marfan syndrome | 2021-03-01 | criteria provided, single submitter | research | PM2, PS6, PP4 |
Invitae | RCV003767926 | SCV004570974 | pathogenic | Marfan syndrome; Familial thoracic aortic aneurysm and aortic dissection | 2024-01-06 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid, which is acidic and polar, with tyrosine, which is neutral and polar, at codon 490 of the FBN1 protein (p.Asp490Tyr). This variant also falls at the last nucleotide of exon 12, which is part of the consensus splice site for this exon. This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with clinical features of FBN1-related conditions (PMID: 11826022, 20886638, 35058154; Invitae). ClinVar contains an entry for this variant (Variation ID: 549019). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Center for Medical Genetics Ghent, |
RCV000663461 | SCV000786755 | uncertain significance | Marfan syndrome | 2017-11-07 | no assertion criteria provided | clinical testing |